StudyKIK to Aid in Patient Recruitment Process as Preferred Recruitment Provider for Midwest Research Group
Costa Mesa, California (PRWEB) February 14, 2017 -- Midwest Research Group has recently chosen StudyKIK, a clinical trial patient recruitment company that specializes in connecting quality patient groups through social media communities to clinical research sites, as their preferred recruitment provider. StudyKIK will assist in the patient recruitment process for Midwest Research Group’s various clinical trials for a wide range of health conditions.
“StudyKIK is our preferred method of patient recruitment because it is our most reliable recruitment tool to find qualified candidates for clinical research studies!” stated Jason Kirkpatrick of Midwest Research Group.
Midwest Research Group helps develop new tools for the treatment of a variety of mental health conditions like Depression, ADHD, Bipolar Disorder, Schizophrenia, Sleep Disorders and Anxiety, to name a few. Now, as their preferred recruitment provider, StudyKIK will gain access to ongoing clinical trials per year run by Midwest Research Group and their parent company, St. Charles Psychiatric Associates. Through this new partnership, StudyKIK will use their network of resources to help bring patients to Midwest Research Group’s various research sites.
"We are excited that Midwest Research Group who is a leader in mental health clinical research has selected StudyKIK as their preferred recruitment provider for 2017,” said Matt Miller, VP Global Patient Recruitment & Feasibility at StudyKIK. “We want to continue to send people to research sites that are experts in the therapeutic areas provide the patient the best research experience possible."
StudyKIK continues to focus on expanding the awareness of clinical trials globally while providing research sites with as many tools as possible to enroll clinical trial volunteers. To learn more about StudyKIK, visit StudyKIK.com.
Matt Miller, StudyKIK, https://www.studykik.com, +1 8776272509, [email protected]
Share this article